Quarterly report pursuant to Section 13 or 15(d)

Disclosure of Correction of Immaterial Error (Summary of Reclassifications) (Details)

v3.21.2
Disclosure of Correction of Immaterial Error (Summary of Reclassifications) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Operating expense:    
Cost of goods sold $ 40 $ 107
Research and Development 2,511 1,862
General and administrative 6,634 5,365
Total operating expenses 9,145 7,227
Eliminations [Member]    
Operating expense:    
Cost of goods sold 0 0
Research and Development (477) (218)
General and administrative (60) (230)
Biopharmaceuticals (iBio, Inc.) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold 0 54
Research and Development 1,521 235
General and administrative 3,484 2,672
Bioprocessing (iBio CDMO) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold 40 53
Research and Development 1,467 1,845
General and administrative $ 3,210 2,923
Statement of Operations Reclassifications [Member]    
Operating expense:    
Cost of goods sold   107
Research and Development   1,862
General and administrative   5,365
Total operating expenses   $ 7,334
Cost of goods sold, % change   100.00%
Research and Development, % change   6.00%
General and administrative, % change   (4.00%)
Statement of Operations Reclassifications [Member] | As Reported [Member]    
Operating expense:    
Cost of goods sold   $ 0
Research and Development   1,762
General and administrative   5,572
Total operating expenses   7,334
Statement of Operations Reclassifications [Member] | Reclassification, Adjustment [Member]    
Operating expense:    
Cost of goods sold   107
Research and Development   100
General and administrative   (207)
Segment Reporting Reclassifications [Member]    
Operating expense:    
Cost of goods sold   107
Research and Development   1,862
General and administrative   5,365
Segment Reporting Reclassifications [Member] | Eliminations [Member]    
Operating expense:    
Cost of goods sold   0
Research and Development   (218)
General and administrative   (230)
Segment Reporting Reclassifications [Member] | Biopharmaceuticals (iBio, Inc.) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold   54
Research and Development   235
General and administrative   2,672
Segment Reporting Reclassifications [Member] | Bioprocessing (iBio CDMO) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold   53
Research and Development   1,845
General and administrative   2,923
Segment Reporting Reclassifications [Member] | As Reported [Member]    
Operating expense:    
Cost of goods sold   0
Research and Development   1,762
General and administrative   5,572
Segment Reporting Reclassifications [Member] | As Reported [Member] | Eliminations [Member]    
Operating expense:    
Cost of goods sold   0
Research and Development   (218)
General and administrative   (230)
Segment Reporting Reclassifications [Member] | As Reported [Member] | Biopharmaceuticals (iBio, Inc.) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold   0
Research and Development   342
General and administrative   2,672
Segment Reporting Reclassifications [Member] | As Reported [Member] | Bioprocessing (iBio CDMO) [Member] | Operating Segments [Member]    
Operating expense:    
Cost of goods sold   0
Research and Development   1,638
General and administrative   $ 3,130